Results 171 to 180 of about 98,545 (284)

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. [PDF]

Sci Rep
Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM.   +3 more
europepmc   +1 more source

Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study

Diabetic Medicine, EarlyView.
In a nationwide cohort of 10,614 patients with metabolic dysfunction–associated steatotic liver disease (MASLD) hospitalized for cardiovascular disease (CVD), diabetes was present in 4550 patients (43%) and was independently associated with higher in‐hospital mortality and cardiovascular complications.
Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita   +11 more
wiley   +1 more source

Fibrosis activity <i>vs</i>. disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease. [PDF]

JHEP Rep
Johansen S, Israelsen M, Thorhauge KH, Hansen JK, Hansen CD, Schnefeld HL, Andersen P, Villesen I, Bech KT, Detlefsen S, Torp N, Leeming D, Thiele M, Krag A, Karsdal M, GALAXY consortia.   +15 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review. [PDF]

Biochem Res Int
Baktikulova K, Kurmangaliyeva S, Tamadon A, Kurmangaliyev K, Mussin NM, Safarzoda Sharoffidin R.   +5 more
europepmc   +1 more source

Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The clinical management of metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH) is undergoing rapid evolution, driven by advances in noninvasive diagnostics and the recent approval of liver‐directed therapies.
Fernando Bril
wiley   +1 more source

Antenatal and Neonatal Management of Siblings With Carbonic Anhydrase VA Deficiency. [PDF]

JIMD Rep
Manoy S, Minto T, Demetriou K, Lynch M, Selvanathan A, Jardine L, Lipke M, Bursle C, Inwood A, McGill J, Coman D.   +10 more
europepmc   +1 more source

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes.
Yuan Li, Weiqi Liu, Yingyu Wang, Bing Wang, Xiang Xu, Bingwei Li, Mingming Liu, Xu Zhang, Ruijuan Xiu   +8 more
wiley   +1 more source

Clinical utility of point-of-care lactate measurement for assessing management status and prognosis in dogs with myxomatous mitral valve disease. [PDF]

Front Vet Sci
Choi W, Ha JY, Jeong ES, Yun YM.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source